Skip to main content
letter
. 2015 Dec 4;5(12):e372. doi: 10.1038/bcj.2015.101

Figure 1.

Figure 1

Survival after first relapse or progression in PMBL patients treated with HDT/ASCT. (a) OS of all patients, (b) PFS of all patients, (c) OS according to disease status, (d) OS according to rituximab-containing treatment, (e) OS according to chemotherapy responsiveness at transplantation, (f) PFS according to chemotherapy responsiveness at transplantation, (g) OS according to relapse <12 months after diagnosis and (h) PFS according to relapse <12 months after diagnosis.